Publications by authors named "Alicia Lopez-Garcia"
Article Synopsis
- The study evaluates the effectiveness and safety of biological therapies for inflammatory bowel disease (IBD) in patients aged 65 and older, addressing a gap in existing research primarily focused on younger populations.
- A total of 1,090 elderly patients were included, with findings showing that a significant portion achieved clinical remission after treatment, particularly by the 52-week mark.
- Although the therapies were generally safe, there was a notable occurrence of oncological events, with variations in incidence rates depending on the specific treatment used.
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders.
Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders.
Design: This was a retrospective and multicentre study.
Background: Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail are limited.
Aims: To compare the durability, effectiveness, and safety of vedolizumab and ustekinumab after anti-TNF failure or intolerance in CD.
Introduction: Intestinal failure is a rare pathology which requires knowledge and highly specialized multidisciplinary management. Crohn's disease (CD) being one of the most frequent causes in adults.
Material And Methods: Survey format study carried out within the GETECCU group, included closed format questions about the diagnosis, management and current knowledge of intestinal failure in CD.
Background And Aims: Clinical trials and real-life studies with ustekinumab in Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data are scarcely available in elderly patients. Therefore, we aim to assess the effectiveness and safety of ustekinumab in elderly patients with CD.
View Article and Find Full Text PDFBackground: Vedolizumab is a humanized monoclonal antibody targeting the αβ integrin used for the treatment of ulcerative colitis. Few biomarkers related to vedolizumab response have been identified. The aim of this work was to assess whether baseline circulating CD4 and CD8 memory T-lymphocyte subpopulations could help to identify patients with response to vedolizumab treatment in ulcerative colitis.
View Article and Find Full Text PDFIntroduction: Small bowel capsule endoscopy (SBCE) is a non-invasive diagnostic technique whose use in inflammatory bowel disease (IBD) has spread. A panenteric capsule, PillCam Crohn's (PCC), has recently been developed. We lack information on the availability and use of the CEID and PCC in our environment.
View Article and Find Full Text PDFBackground And Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life.
Methods: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included.
Background: Methotrexate can be used to maintain remission in Crohn's disease patients who are intolerant to thiopurines. Data on its use as monotherapy in other scenarios are limited.
Aim: To assess the effectiveness of methotrexate monotherapy in Crohn's disease patients after previous failure to anti-tumour necrosis factor (anti-TNFα) drugs.
Background: A significant percentage of patients treated with ustekinumab may lose response. Our aim was to evaluate the short-term efficacy and safety of intravenous re-induction with ustekinumab in patients with Crohn's disease who have lost the response to the treatment.
Methods: This is a retrospective, observational, multicenter study.
Background: There is limited evidence on the effectiveness of biological therapy in stricturing complications in patients with Crohn's disease.
Aim: The study aims to determine the effectiveness of anti-tumor necrosis factor (TNF) agents in Crohn's disease complicated with symptomatic strictures.
Methods: In this multicentric and retrospective study, we included adult patients with symptomatic stricturing Crohn's disease receiving their first anti-TNF therapy, with no previous history of biological, endoscopic or surgical therapy.
Article Synopsis
- Tacrolimus is a medicine used to help prevent organ rejection in transplant patients and may also help people with inflammatory bowel disease (IBD).
- A study in Spain looked at 143 adult patients with IBD who took tacrolimus for 3 months, and many showed improvement in their symptoms.
- Some patients had side effects, and 84% stopped taking the medicine because it stopped working for them, with a small number developing serious issues like cancer.
Article Synopsis
- The study looked at how to find out which patients with Crohn's disease would heal well when treated with special medicines called TNF-α inhibitors.
- They found that a big improvement in a specific test score after 14 weeks was a good sign that the patients would heal well after a year.
- Overall, basic health data didn’t help predict healing, but seeing a major drop in the disease score early on was really important to know who would get better in the long run.
Background And Aims: Recent studies have shown the efficacy of autologous haematopoietic stem cell transplantation [HSCT] in severely refractory Crohn's disease [CD] patients. HSCT is thought to eliminate auto-reactive cells; however, no specific studies of immune reconstitution in CD patients are available.
Methods: We followed a group of CD patients [n = 18] receiving autologous HSCT, with 50% of them achieving endoscopic drug-free remission.
Background: Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn's disease [CD] unresponsive to currently available therapies.
Methods: Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years.
Background: Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors of remission to ADA.
Methods: This cohort study used data from the ENEIDA registry.
Introduction: Fecal calprotectin (FC), as determined by the enzyme-linked immunoassay (ELISA) test, has been proposed as a promising biomarker of endoscopic activity in Crohn's disease (CD). However data on its accuracy in predicting endoscopic remission according to location and postoperative recurrence (POR) is scarce. Our objective was to evaluate the ability of FC determined by a new quantitative point-of-care test (FC-QPOCT) to predict endoscopic remission and POR in CD patients.
View Article and Find Full Text PDF